COVID-19 + Грипп А/В антиген, экспресс-тест

Home
/
LFA Rapid Tests
/
RAPID COVID-19 + Influenza A/B Ag

RAPID COVID-19 + Influenza A/B Ag

Registration Certificate: No. RZN 2023/20 953

A lateral flow immunoassay for rapid, simultaneous qualitative detection and differentiation of coronavirus SARS-CoV-2, Influenza A, and Influenza B viral antigens extracted from the nasopharyngeal swab in individuals who are suspected of respiratory infection consistent with COVID-19 and/or Flu.

RAPID COVID-19 + Influenza A/B Ag

Registration Certificate: No. RZN 2023/20 953

A lateral flow immunoassay for rapid, simultaneous qualitative detection and differentiation of coronavirus SARS-CoV-2, Influenza A, and Influenza B viral antigens extracted from the nasopharyngeal swab in individuals who are suspected of respiratory infection consistent with COVID-19 and/or Flu.

Submit a Request

The Current Diagnostic Landscape

The Dual Challenge of Seasonal Influenza
Influenza remains a primary public health concern, characterized by the simultaneous circulation of Influenza A and B strains. In the 2025−2026 season, Influenza A (H3N2) — known for its high clinical severity — and Influenza B (including Victoria and Yamagata lineages) continue to drive seasonal morbidity. Influenza B, in particular, remains a significant threat to pediatric populations, often leading to severe respiratory complications.

The Post-Pandemic Landscape of COVID-19
Following the termination of the WHO Public Health Emergency, SARS-CoV-2 has transitioned into an endemic phase. The virus continues to evolve through persistent mutational shifts, causing periodic infection surges. The overlapping symptoms of COVID-19, Influenza, and other ARVIs (Acute Respiratory Viral Infections) make clinical diagnosis based on symptoms alone highly unreliable.

Precision Diagnostics with Rapid Bio
Differential diagnosis is critical for selecting appropriate antiviral therapies and preventing outbreaks. The Rapid COVID-19+Influenza A/B Test is engineered to meet current diagnostic challenges.

Clinical Impact & Benefits

01

Differential Diagnosis of COVID-19, Influenza, and Other ARVIs

The simultaneous circulation of multiple respiratory pathogens makes symptom-based diagnosis highly inaccurate. Rapid testing is essential to prevent clinical misdiagnosis and over-prescription of antibiotics, thereby reducing the strain on healthcare facilities and preventing unnecessary hospitalizations.

02

Outbreak Prevention in Communal and Clinical Settings

Timely diagnostic screening in healthcare facilities, educational institutions, and workplaces is critical for early detection. This enables the rapid implementation of infection control measures, effectively breaking the chains of transmission and protecting vulnerable populations (the elderly, children, and immunocompromised patients).

03

Optimized Early-Stage Treatment

The efficacy of antiviral therapy for Influenza A and B is highly dependent on early administration. Laboratory confirmation within the first 24−48 hours of symptom onset allows for the immediate initiation of targeted treatment, significantly reducing the duration of illness and the risk of severe secondary complications (such as viral pneumonia).

Преимущества теста

Optimized for early-stage screening of patients presenting with ARVI symptoms, as well as for monitoring individuals following confirmed contact with infected cases

Provides clear differentiation between Influenza A/B, COVID-19. This precision prevents clinical misdiagnosis, discourages unnecessary antibiotic therapy, and reduces the burden of avoidable hospitalizations

Supports robust public health surveillance by providing real-time data on influenza prevalence. This allows healthcare administrators to effectively allocate medical resources and prepare for seasonal surges

Delivers diagnostic results within minutes, enabling healthcare providers to determine the optimal treatment strategy and infection control measures without delay

This integrated 'all-in-one' test cassette features distinct control lines for multiple viruses, ensuring diagnostic reliability while simplifying procedures for both clinical and field use

Specifications

Time to Result

6−8 minutes

Analytical Sensitivity (LoD):

SARS-CoV-2: 0.2 ng/mL
Influenza A/B: 10.0 ng/mL

Reproducibility

100%

Shelf Life:

24 months

Instructions for Use

User Manual

Download

Graphic Instructions

Download

Interpretation

Negative Result

Only the control line “C” appears in the test window. No color appears on the test line “S”, “A”, or “B”.

Positive Result

Two or three colored lines appear in the test window: the control line “C” and the test line “S”, “A”, or “B”.
The color intensity of the test lines may vary.

Invalid Result

The control line “C” does not appear in the test window, regardless of whether the test line “S”, “A”, and/or “B” is present.

An invalid result may be caused by incorrect performance of the test procedure or by the unsuitability of the medical device. In this case, it is recommended to repeat the testing procedure.